Mark Marsico1, Vinay Mehta, Benjamin Chastek, Kai-Li Liaw, Craig Derkay. 1. From the *Epidemiology Department, Merck Research Laboratories, North Wales, PA; †OptumInsight, Eden Prairie, MN; and ‡Department of Otolaryngology, Pediatric Otolaryngology, Eastern Virginia Medical School Children's Hospital of the King's Daughters, Norfolk, VA.
Abstract
BACKGROUND: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a chronic disease caused by human papillomavirus types 6 and 11. It is associated with significant morbidity that places intense physical, psychological, and financial strain on patients and their families. Few studies have assessed the incidence and prevalence of JORRP in the United States. METHODS: This retrospective, longitudinal cohort study was performed using data from a pair of large insurance claims databases in the United States. The Optum Clinformatics and Truven MarketScan Medicaid databases represent a sample of privately and publicly insured children, respectively. Cohorts of children aged 0 to 17 years were created within each database to estimate the incidence and prevalence of JORRP in 2006. Claims-based algorithms were designed to capture as many potential cases as possible. To improve the accuracy of the incidence and prevalence estimates, chart validation was performed to estimate the positive predictive value (PPV) of the claims-based algorithms. RESULTS: The overall PPV-adjusted incidence of JORRP in 2006 was 0.51 per 100,000 in Optum and 1.03 per 100,000 in the MarketScan Medicaid population. Peak incidence was observed among 0- to 4-year-olds in both databases. The PPV-adjusted prevalence of JORRP in 2006 was 1.45 and 2.93 per 100,000 in the Optum and MarketScan Medicaid cohorts, respectively. CONCLUSIONS: Although relatively uncommon, JORRP represents a disease with significant morbidity. The incidence and prevalence of JORRP in publicly insured children were consistently higher than those covered by private insurance plans, suggesting an increased burden of illness among those with lower socioeconomic status.
BACKGROUND: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a chronic disease caused by human papillomavirus types 6 and 11. It is associated with significant morbidity that places intense physical, psychological, and financial strain on patients and their families. Few studies have assessed the incidence and prevalence of JORRP in the United States. METHODS: This retrospective, longitudinal cohort study was performed using data from a pair of large insurance claims databases in the United States. The Optum Clinformatics and Truven MarketScan Medicaid databases represent a sample of privately and publicly insured children, respectively. Cohorts of children aged 0 to 17 years were created within each database to estimate the incidence and prevalence of JORRP in 2006. Claims-based algorithms were designed to capture as many potential cases as possible. To improve the accuracy of the incidence and prevalence estimates, chart validation was performed to estimate the positive predictive value (PPV) of the claims-based algorithms. RESULTS: The overall PPV-adjusted incidence of JORRP in 2006 was 0.51 per 100,000 in Optum and 1.03 per 100,000 in the MarketScan Medicaid population. Peak incidence was observed among 0- to 4-year-olds in both databases. The PPV-adjusted prevalence of JORRP in 2006 was 1.45 and 2.93 per 100,000 in the Optum and MarketScan Medicaid cohorts, respectively. CONCLUSIONS: Although relatively uncommon, JORRP represents a disease with significant morbidity. The incidence and prevalence of JORRP in publicly insured children were consistently higher than those covered by private insurance plans, suggesting an increased burden of illness among those with lower socioeconomic status.
Authors: Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova Journal: Proc Natl Acad Sci U S A Date: 2019-09-04 Impact factor: 11.205
Authors: Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya Journal: Hum Vaccin Immunother Date: 2016-02-18 Impact factor: 3.452
Authors: Martin Formánek; Pavel Komínek; Debora Jančatová; Lucia Staníková; Radoslava Tomanová; Jana Vaculová; Milan Urík; Ivo Šlapák; Karol Zeleník Journal: Biomed Res Int Date: 2019-02-10 Impact factor: 3.411
Authors: Shelagh M Szabo; Katherine Gooch; Carol Schermer; David Walker; G Lozano-Ortega; Basia Rogula; Alison Deighton; Edward Vonesh; Noll Campbell Journal: BMJ Open Date: 2019-05-05 Impact factor: 2.692
Authors: Elissa Meites; Laura Stone; Raiza Amiling; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz Journal: Clin Infect Dis Date: 2021-09-07 Impact factor: 20.999